Drug profile · INN
azathioprine
APO-AZATHIOPRINE
azathioprine (APO-AZATHIOPRINE) is a amidophosphoribosyltransferase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — azathioprine
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- ORAL
- Patents
- 0
- Programs
- 20
- Data quality
- 0.89
Quick answer
azathioprine (APO-AZATHIOPRINE) is a amidophosphoribosyltransferase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Amidophosphoribosyltransferase inhibitor
Primary target: Amidophosphoribosyltransferase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Congress & event coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is azathioprine?
azathioprine (APO-AZATHIOPRINE) is a amidophosphoribosyltransferase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for azathioprine?
APO-AZATHIOPRINE is a marketed brand name for azathioprine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of azathioprine?
azathioprine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.